23 Jul 2018 07:00
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notice of Results
London, 23 July 2018 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, will announce its interim results for the six months ended 30 June 2018 on Wednesday 8 August 2018.
A meeting and webcast for analysts will be held at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD at 1.00pm BST/8.00am EST. To join via conference call please dial:
United Kingdom Toll-Free: 08003589473
United Kingdom Toll: +44 3333000804
United States Toll-Free: +18558570686
United States Toll: +1 6319131422
Participant PIN code: 63533328#
The results presentation and a webcast recording of the event can be accessed via:
https://arkadin-event.webex.com/arkadin-event/onstage/g.php?MTID=e7132326c86ef296f9b815298b1f34136
Event password: 301238202
Enquiries:
Mereo BioPharma Group plc | +44 (0)333 023 7300 |
Denise Scots-Knight, Chief Executive Officer | |
Richard Jones, Chief Financial Officer | |
Cantor Fitzgerald Europe (Nominated Adviser and Broker) | +44 (0)20 7894 7000 |
Phil Davies | |
Will Goode | |
Rick Thompson | |
RBC Capital Markets (Joint Broker) | +44 (0)20 7653 4000 |
Rupert Walford | |
FTI Consulting (Public Relations Adviser) | +44 (0)20 3727 1000 |
Simon Conway | |
Brett Pollard | |
Burns McClellan (US Public Relations Advisor to Mereo Biopharma) | +01 (0) 212 213 0006 |
Lisa Burns |
|
Steven Klass |
|
About Mereo
Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. The portfolio consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 for the treatment of osteogenesis imperfecta ("OI"); MPH-966 (formerly AZD-9668) for the treatment of severe alpha-1 antitrypsin deficiency ("AATD"); BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, ("AECOPD"); and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH") in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and announced positive top-line results from two of these studies, a Phase 2 clinical trial of BCT-197 as an acute therapy for patients with AECOPD in December 2017 and a Phase 2b dose-ranging study with BGS-649 for the treatment of HH in March 2018.